vitamin D levels and mortality mainly occurs in patients with a high magnesium intake.
The aim of the study was to assess the mechanisms involved by determining whether magnesium alone or combined with calcitriol treatments differentially impact vascular calcification (VC) in male Sprague-Dawley rats with adenine-induced CKD. Treatment with moderate doses of calcitriol (80ug/kg) suppressed PTH to near or slightly below control levels. Given alone, this dose of calcitriol increased the prevalence of VC; but when magnesium was given in combination, the severity of calcification was attenuated in the abdominal aorta (51% reduction), iliac (44%) and carotid arteries (46%) compared to CKD controls. The decreases in vascular calcium content were associated with 20-50% increase in vascular Mg. Calcitriol treatment alone significantly decreased TRPM7
protein (↓ to ~11%) whereas the combination treatment increased both the mRNA (1.7X) and protein (6.8X) expression compared to calcitriol alone. In summary, calcitriol increased VC in certain conditions; but magnesium prevented the reduction in TRPM7
and reduced the severity of VC, thereby increasing the bioavailable magnesium in the vascular microenvironment. These findings suggest that modifying the adverse effect profile of calcitriol with Mg may be a plausible approach to benefiting the increasing number of CKD patients being prescribed calcitriol.
Introduction
Vascular calcification (VC) is a common manifestation of cardiovascular disease (CVD) in chronic kidney disease (CKD) (Foley and Parfrey, 1998; Jono et al., 2006) .
Aberrant mineral metabolism, involving hyperphosphatemia, hyperparathyroidism and vitamin D insufficiency, are hallmarks of progressing CKD. These indicators have been consistently linked to the severity of VC and mortality in these patients (Kestenbaum et al., 2005; Cannata-Andia et al., 2006; Holden et al., 2010) . VC is now recognized as an active mineralization process, involving transformative changes in medial vascular smooth muscle cells (VSMC) and the surrounding microenvironment that negatively impacts the circulation (Giachelli, 2004) . Recent evidence also demonstrates significant cross-talk between endothelial cells and VSMCs through humoral factors, such as angiopoietin 2 and vascular endothelial growth factor (VEGF). These factors have been implicated in the regulation of vascular function in health and various disease states, for example vascular calcification (Bourque et al., 2011; David et al., 2012; Yao et al., 2013; Chang et al., 2014) .
The mineral magnesium also plays an important role in various aspects of cellular physiology, including the regulation of vascular tone, cardiac electrophysiology, and bone metabolism. Magnesium entry into these tissues is regulated, at least in part, by the activity of the transient receptor potential melastatin 7 cation channel (TRPM7), a divalent ion transporter with a high affinity for magnesium. In population-based studies, magnesium deficiency has been implicated in several disorders such as diabetes, (Garg et al., 2014) hypertension (Cunha et al., 2012) and CVD (Reffelmann et al., 2011.) Although not currently considered to be a hallmark of CKD, abnormal serum magnesium has also ADDJCBH G been associated with increased cardiovascular events and mortality in end stage renal disease patients (ESRD) (Navarro-Gonzalez et al., 2009; Kanbay et al., 2012) . Despite these associations, the mechanism by which magnesium attenuates the progression and development of VC in CKD has not been well studied. Mechanistically linking abnormalities in magnesium regulation with CVD could be important, as several in vitro studies have demonstrated that magnesium has the potential to attenuate hydroxyapatite growth, the basic building block of calcification (Cheng et al., 1988; Kircelli et al., 2012; Louvet et al., 2013) . These studies also showed that magnesium up regulated anticalcification proteins, and prevented VSMC trans-differentiation into an osteoblast-likephenotype. Using a 5/6-nephrectomy model to induce experimental CKD, Inagaki et al.
(1996) investigated whether in vivo magnesium supplementation attenuated VC. Their results were not definitive as the CKD phenotype in their model lacked hyperphosphatemia, hyperparathyroidism, and frank VC. Despite this limitation they found that aortic calcium content, but not phosphate, was slightly higher in animals on a magnesium deficient diet (Inagaki et al., 1996) ; a finding that may or may not be generalizable to other models (Shobeiri et al., 2010) . Further studies are needed to investigate whether magnesium treatment beneficially impacts CKD in a model in which all the key aspects of the pathogenic phenotype are evident.
Magnesium has also been implicated in vitamin D synthesis and metabolism.
Magnesium is as a cofactor for vitamin D binding protein in the serum, as well as a modulator of the expression and activities of 1-α-hydroxylase and 25-hydroxlase (Risco and Traba, 1992 et al., 2007) . This relative increase in vascular magnesium suggested there was a potential interaction between magnesium and vitamin D receptor activation. Vitamin D insufficiency is a well-established occurrence in the progression of CKD, and has been linked to hyperparathyroidism and adynamic bone disease in these patients (Helvig et al., 2010; Holden et al., 2010) . Furthermore, clinical studies have found that treatments with vitamin D receptor activators, such as calcitriol, reduce the risk of mortality in early-stage CKD patients and ESRD patients on dialysis treatments (Duranton et al., 2013) . However, more recent evidence from the National Health and Nutrition Examination Survery (NHANES) and confirmed by Mursu et al. (2015) indicate that the association between serum 25(OH)D and mortality is modified by magnesium intake (Deng et al., 2013; Mursu et al., 2015) . The inverse relationship between mortality and vitamin D levels was only identified in patients with high magnesium intake. Together, these data suggest a mechanistic interaction between magnesium and vitamin D is likely but the scope of this interplay requires further elucidation.
Despite the reported beneficial effects of calcitriol in clinical studies, most studies in experimental CKD have shown that calcitriol exacerbates hypercalcemia, hyperphosphatemia and increases the severity of VC (Jono et al., 1998; Cardus et al., 2007; Koleganova et al., 2009) . This calcitriol paradox likely relates to the dose, as amounts below 30ng/kg have been shown to reduce VC (Mathew et al., 2008; Lau et al., 2012 ) whereas higher doses induce VC (Cardus et al., 2007; Koleganova et al., 2009; Duranton et al., 2013) . These data suggest that calcitriol has a very narrow therapeutic ADDJCBH I window, thereby limiting its utility and benefit in therapy. Expanding and defining the beneficial therapeutic window for vitamin D type treatments would clearly be clinically useful. The present study hypothesizes that magnesium has a potential role as an adjunct treatment in CKD by attenuating the adverse actions of calcitriol. To test this concept, the present study was designed to determine whether changes in dietary magnesium status (to reflect likely translational approaches), alone or in combination with calcitriol treatment impacts the susceptibility to and/or severity of VC in a rodent model of adenine-induced CKD.
Methods

Animal Preparation:
All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US national Institutes of Health, the guiding principles of the Canadian Council on Animal Care (CCAC) and with the approval of the Queen's University Animal Care Committee (UACC).
Male Sprague-Dawley rats (n=32, 14 weeks of age) were individually housed and maintained on a 12-h light/dark cycle. All animals were acclimatized for a one week period prior to the study during which they were provided with standard rat chow (LabDiet 5001, Ren's Pets Depot, Oakville, ON, Canada) and water ad libitum. At 15 weeks of age, CKD was generated using an adenine model as previously described (McCabe et al., 2013; Shobeiri et al., 2013) . Briefly, the standard rat chow was weeks of giving adenine to induce CKD, rats were stratified according to serum creatinine levels and then allocated by rank into one of four groups ensuring that there were equivalent average level and range of kidney dysfunction at the onset of the treatments.
Animals were stratified into one of 4 treatment groups; ensuring that each group had. For the next 4 weeks, each group was maintained on: 1) regular adenine diet (CKD; 0.25% adenine, 0.05% Mg food, n=8), 2) high magnesium diet (CKD-M; 0.25% adenine + 0.2% Mg food, n=8), 3) calcitriol (CKD-C; 80ng/kg/day, 0.25% adenine, n=8), or 4) high dietary magnesium (CKD-CM; 0.25% adenine + 0.2% Mg food) + calcitriol (80ng/kg/day, n=8). Weights and food intake were monitored on a daily basis, and animals were supplemented with normal chow and/or Nutri-Cal if a decline in body weight reached 10%. These supplements do not contain increased amounts of calcitriol, any form of vitamin D, magnesium or vitamin K. At 7 weeks (3-7 week treatment interval) rats were sacrificed under a high level of general anesthetic (5% isoflurane).
Blood was drawn (8-10 ml) using a 22g hypodermic needle inserted into the left ventricle of the heart while the animal was under anesthesia. The heart was excised and right ventricle was separated from the left ventricle at the septum. The following tissues were rapidly collected, cleaned, and weighed: left and right ventricle, thoracic aorta, abdominal ADDJCBH K aorta, renal artery, carotid artery, superior mesenteric artery and iliac artery. Tissues were collected and snap-frozen in liquid nitrogen and stored at -80 0 C for further analysis.
Calcitriol and Magnesium Dosages:
The clinical dose of calcitriol, converted to rat equivalent doses based on body surface area, is approximately 15-50 ng/kg/day. Based on preliminary dose-ranging studies, the selected moderately high dose of 80 ng/kg/day was found to meet the target criteria for promoting a mild adverse event profile including vascular calcification, mild hypercalcemia and suppression of PTH to near normal levels. The overarching goal of the present studies was to determine whether adjunct treatment with high dietary magnesium could attenuate the development of these calcitriol-induced characteristics in CKD.
In healthy humans, the normal range of total serum magnesium is ~0.65-1.05mmol/L. In the present study, the CKD rats on the adenine diet alone (0.05%mg diet)
had serum magnesium levels of 1.38±0.7 mmol/L. The animals on the high magnesium diet (0.2% mg diet) had serum magnesium of 1.72 ± 0.3. This amount of magnesium was well tolerated by the animals and did not cause any obvious abnormalities such as diarrhea or seizures. Preliminary in vitro assessments using aortic ring vessel segments in DMEM showed that magnesium concentration-response (0.8 to 2.5 mM) had a protective effect against vascular calcification starting between 1.38mM and 1.72mM.
Hemodynamic measurements:
ADDJCBH CB Prior to sacrifice, the animals were anesthetized to a surgical plane using isoflurane (2.5%). Rats body temperature was maintained at 37 o C using a thermistor temperature controller, and heating pad (Yellow Springs Instruments, Yellow Springs, OH). Pulse wave velocity (PWV) was assessed using the foot-to-foot method as previously described (Shobeiri et al., 2013) . Briefly, two catheters were inserted into the superior (via carotid) and inferior (via iliac) portion of the aorta and arterial pressure was recorded as a pulsatile waveform (1000Hz) using Chart version 5 software. Arterial pressure was measured using PE-50 heparinized (50IU/mL) saline-filled cannula (ID 0.58mm, OD 0.965mm; Belton Dickson, Sparks, MD), and the distance between the tips of superior and inferior catheters was measured using 1-0 silk stretched between the two points.
PWV was measured as (propagation distance)/(propagation time) between the superior and inferior catheter placements. At least 10 consecutive waveforms at each time point were individually analyzed then averaged. Systolic blood pressure, diastolic blood pressure and pulse pressure were measured from the carotid catheter. PWV was normalized to diastolic pressure to account for the known dependency of this variable on changes in arterial pressure (Spronck et al., 2015) .
Vessel Phosphate, Calcium and Magnesium Content:
Vessels were weighed, and then fully dissolved in 1.0 N hydrochloric acid for 24h at 4 0 C.
The samples were then spun and the calcium content was determined colorimetrically using the O-cresolphthalein complexone method (Sigma-Aldrich Canada Co., Oakville, ON, Canada). This reagent generates a purple color when in a complex with calcium; the linear range of detection is at least 40 fold. The absorbance for this complex was measured for both standards and the tissue homogenates at 540nm (SynergyHT
ADDJCBH CC
Microplate Reader, Bio-Tek Instruments, Winooski, VT). Tissue phosphate levels from the same samples as calcium were quantified using the malachite green method as previously described (Heresztyn and Nicholson, 2001) . In brief, when ammonium molybdate is added, a green complex containing malachite green, molybdate, and free phosphate forms. The absorbance for this complex was measured for standards, tissue
homogenates and plasma at 650 nm. Magnesium content was quantified colorimetrically using a modified Magnesium Reagent Kit (Pointe Scientific Inc., Canton, MI). Briefly, in this assay, magnesium ions react with xylidyl blue in an alkaline solution to produce a red complex that is measure spectrophotometrically at an absorbance of 530nm.
Blood Biochemistry:
Blood from the saphenous vein was obtained from all animals to measure serum creatinine and phosphate at baseline, 3, 5, and 7 weeks of adenine treatment, to track the progression of CKD. At the end of the experiment, serum calcium and magnesium were also determined. Creatinine levels were measured using the QuantiChrom Creatinine Assay Kit (DICT-500) (BioAssay Systems, Hayward, CA). Serum phosphate, calcium and magnesium assays were the same as for tissue samples.
At sacrifice (7 weeks), serum and plasma were procured from cardiac puncture for subsequent analysis. Parathyroid hormone (PTH) and FGF-23 (C-Term) concentration were measured using a commercially available Rat Intact Elisa (Immutopics, Clemente, California). Angiopoietin 2 was measured in serum using a commercially available Rat
Quantikine Elisa kit (R&D Systems, Minneapolis, Minnesota)
Western Blot Analysis:
This article has not been copyedited and formatted. The final version may differ from this version. Western blot was performed. The gels were probed with rabbit anti-mouse RUNX2
antibody (1:5000 dilution, sc-10758; Santa Cruz Biotechnology, Santa, Cruz, CA) overnight and incubated in secondary (1:20000 dilution, goat anti-rabbit immunoglobulins HRP (Dako) antibody for 1 hr at room temperature. As a loading control, the blots were probed with anti-β-actin antibody HRP (1:10000 dilution, ab20272; Abcam Inc., Cambridge, MA) for 1 hr. TRPM7 and RUNX2 protein expression was expressed relative to the loading control and an internal control. Densitometry using
ImageJ was used to quantify relative protein levels.
Real-time Polymerase Chain Reaction:
RNA was extracted using QIAGEN RNeasy Minikit (Canada -QIAGEN Inc., Hercules, NY, USA) and expression data was analyzed using CFX Manager Software (Bio-Rad). Expression levels were calculated using the 2(-Delta Delta C(T)) method and normalized to β-actin expression levels (Schmittgen and Livak, 2008) . Data are expressed relative to non-CKD age match controls.
Von Kossa method of assessing vascular calcification
Sections of abdominal aorta were fixed in neutral phosphate-buffered saline (10x) with 4% paraformaldehyde prior to embedding in paraffin. Embedded tissue was sectioned into five micrometer segments and placed on a glass slide. Vascular calcification was visualized using the Von Kossa method (McCabe et al., 2013) .
Statistical analysis
Statistical analysis and graphical representation was performed using GraphPad Prism 6.0. Figure 3 and Figure 8 were presented as mean ± standard error of the mean (SEM).
All other data were presented as mean ± standard deviation (SD). Statistical differences between treatment groups were determined with a two-way analysis of variance ADDJCBH CF (ANOVA). As required, a Tukey correction was used for post hoc comparison of means for significant interaction. Data were log transformed to normalize distribution prior to statistical analysis (one way ANOVA) when required. P <0.05 was considered to be significantly different.
Results
Results of the biochemical analyses of serum samples appear in Figure 1 and weeks of CKD, total serum calcium levels were significantly elevated with calcitriol treatments. There was significant interaction between magnesium and calcitriol treatments on serum calcium, indicating that magnesium differentially modified calcium homeostasis (↓) in calcitriol treated rats (p<0.05, Figure 2A ). There was a significant main effect of calcitriol (↑ 32%) and magnesium (↑ 24%) treatments on serum magnesium (p<0.05, Figure 2B ). As expected, calcitriol treatment significantly suppressed PTH towards control levels and FGF-23 was significantly elevated (8.8X, Figure 2C /D) compared to the non-calcitriol groups (p<0.05). There was an overall main This article has not been copyedited and formatted. The final version may differ from this version. calcitriol; p<0.05). There was also a significant main effect (↓ by 20%) of magnesium treatment on angiopoietin 2 levels (p<0.05).
Haemodynamic Consequences of Treatment:
Although there was no difference in mean arterial pressure (MAP) between treatment groups ( Figure 3A ), calcitriol treated rats had significantly elevated systolic blood pressure (SBP, Figure 3C ; p<0.05), decreased diastolic blood pressure (DBP, Figure 3D , p<0.05) resulting in significantly increased pulse pressures ( Figure 3B ). The effects were most evident in changes to pulse wave velocity (PWV, Figure 3F ); i.e. calcitriol alone induced a 4.2 fold elevation in PWV versus controls whereas magnesium-calcitriol treatment only induced a 2.0 fold increase versus the magnesium treated control (p<0.05).
Vascular Calcification:
To test the hypothesis that calcitriol and magnesium treatments modify vascular calcification severity in CKD, calcium and phosphate content was measured in the thoracic and abdominal aorta and iliac, carotid, renal, and superior mesenteric arteries (Figure 4) . A main effect of calcitriol treatment was observed, such that treatments increased VC severity in four of the six vessel segments studied: thoracic aorta and carotid, renal and iliac arteries (p<0.05). To test whether magnesium status can further with calcium content in a ratio predicted by hydroxyapatite crystal formation ( Figure 5 ).
Staining of the vessels with von Kossa confirmed the presence of severe VC that was localized to the vascular media. Figure 6 shows representative images of the abdominal aorta from the different treatment groups.
Vascular Magnesium Status:
To determine whether calcitriol or magnesium treatments modify vascular magnesium status, magnesium content was measured across the vasculature (Figure 7 ).
Calcitriol treatments significantly increased magnesium content in the thoracic aorta and the iliac, carotid and renal arteries (p<0.05). Post hoc analysis did not identify any effect of magnesium treatment on total vascular magnesium content. However, magnesium is incorporated stoichiometrically into the vasculature throughout the VC process (data not 
Gene and Protein analysis:
Analysis of the mRNA ( Figure 9A ) and protein ( Accordingly, careful monitoring of PTH and mineral levels, in particular, is important to avoid the iatrogenic adverse effects of these treatments and to emphasize the beneficial effects. In the current study, a key objective was to assess whether the negative impact of a moderate dose of calcitriol (80 ng/kg/day), previously shown to cause symptoms of ADDJCBH CK calcitriol toxicity, namely hypercalcemia, PTH over-suppression and VC, could be modified by concomitant magnesium (Krejs et al., 1983; Koleganova et al., 2009; Helvig et al., 2010; Lau et al., 2012) . The results confirmed the anticipated dose-dependent, calcitriol-induced pathogenesis in this adenine model of CKD: i.e. suppression of PTH back to control levels, increased serum calcium by ~35% (but not serum phosphate), elevated FGF-23 and increased VC, with consequent increases in systolic blood pressure, pulse pressure and PWV. Angiopoietin-2 is a growth factor specific for the vascular endothelium, and is an important regulator of inflammation (Chang et al., 2014) .
Angiopoietin-2 is elevated in CKD patients and has been associated with mortality and vascular stiffness in these patients (David et al., 2012; Chang et al., 2014) . Work is currently underway to elucidate the direct effect of angiopoietin-2 on vascular calcification. The present study demonstrates the calcitriol decreases angiopoietin-2 levels, and is further modified by magnesium status. Although speculative, it is possible that magnesium, which has anti-inflammatory properties (Moslehi et al., 2012) , also inhibits VC through angiopoietin-2 dependent pathways.
The selected dose of calcitriol (Inagaki et al., 1995; Henley et al., 2005) clearly increased the susceptibility of vessels to VC, and to the associated pathogenic haemodynamic alterations (increased PWV, PP). Although this study did not elucidate the specific mechanism by which calcitriol increases the susceptibility of vessels to calcification, the findings did reveal that hallmark increases in FGF-23 and serum evidence suggests that this beneficial effect might only be in patients that have a high magnesium intake (Deng et al., 2013) . Importantly, the present findings are consistent with this concept, demonstrating for the first time, that combining magnesium treatment with calcitriol, reduces the severity of both hypercalcemia and vascular calcification in conductance and peripheral vascular beds. Interpreting the mechanism underlying the increased severity of VC with calcitriol alone is complicated by the finding that serum magnesium is increased with this treatment. However, evidence is emerging that it is the concentration of magnesium at the tissue level that is critical and this level does not necessarily directly reflect the circulating milieu (Lim et al., 1969; Montezano et al., 2010) Several in vitro vascular studies have identified magnesium as a potential anticalcification moiety (Ennever and Vogel, 1981; Cheng et al., 1988; Montezano et al., 2010) . The present study extends and confirms the previous in vitro findings to in vivo using an approach that uses a moderate level of magnesium supplementation to attenuate VC severity in various arteries. The mechanism of inhibition is likely dependent on the entry of magnesium into the vascular microenvironment, a process thought to be regulated, at least in part, by the transient receptor potential melastatin 7 cation channel (TRPM7). TRPM7 is a divalent ion transporter with a high affinity for magnesium. The overall decrease in the Ca:Mg ratio in magnesium-treated rats provides evidence of a differential effect on magnesium levels in the vascular microenvironment . Levels of intracellular magnesium are known to inversely affect channel activity through a feedback mechanism involving the phosphotransferase activity of TRPM7's kinase et al., 2003; Macianskiene et al., 2012 ). The present study shows that the CKD rats given calcitriol have markedly lower TRPM7 protein expression in the vasculature compared to untreated controls. Decreased TRPM7 expression could be the key basis for the increased prevalence of VC in calcitriol treated animals, a suggestion supported by previous in vitro studies demonstrating that vessels readily calcify when TRPM7 channels are pharmacologically blocked (Montezano et al., 2010) . Although the decreased expression of this protein herein may be due to the elevated magnesium levels in animals given calcitriol, a direct effect of calcitriol on TRPM7 expression remains to be elucidated. Furthermore, combining calcitriol with magnesium partially rescued the calcitriol-induced suppression of TRPM7 indicating there is significant cross-talk between the pathways. While our results indicate that the improved vascular magnesium status may be dependent, in part, on TRPM7 mediated processes, further research is also needed to confirm this effect.
It is well known that calcium and phosphate accrual occurs in the vascular microenvironment in a stoichiometric manner with increasing VC severity, in both uremic and aged patients (Contiguglia et al., 1973; Ongkana et al., 2007; Matsumoto et al., 2012) . Our findings in rats with adenine-induced CKD confirm that magnesium is also incorporated within crystals of calcifying vascular tissues. In this study, one hypothesis was that for a given vascular calcium level, increasing magnesium content or availability would protect against further progression. Therefore, given that calcium sequestration is actively occurring, vascular magnesium content is more appropriately expressed relative to the calcification severity (Ca/Mg). In a relative magnesium deficient state, vessels exposed to the uremic milieu would readily form the calcium-phosphate ADDJCBH DD complexes, resulting in rapid crystal proliferation (Boskey and Posner, 1980) . In vitro evidence suggests that magnesium does not directly affect hydroxyapatite growth; rather, it acts to stabilize the precursor amorphous calcium-phosphate phase (Nielsen, 1973; Tomazic et al., 1975) . The current study clearly demonstrates that magnesium supplementation increases the magnesium content relative to calcium. The study further demonstrates that magnesium treatment generates a significant reduction in VC severity that is generalizable to both proximal and distal vasculature. The robust reduction in VC severity parallels the increased availability of magnesium relative to calcium in the magnesium treatment groups; an effect which was even more pronounced in the combined calcitriol-magnesium group. Although currently a putative concept, the findings suggests that magnesium co-treatment might be able to extend the therapeutic window for calcitriol therapy in CKD, an outcome which could have important therapeutic implications. Further studies, investigating the full dose-response effects of calcitriol in combination with magnesium, will be required to fully validate this concept.
In addition, the study revealed that combining magnesium with calcitriol can both reduce hypercalcemia and yet similarly suppress PTH, while protecting, at least in part, the vasculature from calcium and phosphate accrual. The results confirm, as predicted, that calcitriol can increase VC under certain circumstances; an effect that is attenuated in the presence of increased magnesium. Importantly, the calcitriol-induced reduction in vascular TRPM7 protein expression was abrogated, at least in part, by magnesium cotreatment. Taken together, these data suggest that the benefit of the combined treatment likely involves (i) preventing reductions in TRPM7 expression and (ii) increasing the relative entry and availability of magnesium (↓Ca:Mg ratio) into the VC susceptible 
